{"schema_version":"secwatch.filing_event.v1","accession":"0001690585-26-000029","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2026-06-12T11:00:32+00:00","discovered_at":"2026-06-12T11:05:01.211014+00:00","generated_at":"2026-06-12T11:05:31.269348+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Dianthus posts corporate presentation with Phase 3 CAPTIVATE interim data for claseprubart in CIDP","bullets":["Interim responder analysis data for first 40 patients from Part A of Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy.","Presentation posted on investor relations website on June 11, 2026.","No specific numeric results disclosed in the filing text; actual data is in the presentation slides."],"urls":{"canonical":"https://secwatch.observer/filing/0001690585-26-000029","json":"https://secwatch.observer/filing/0001690585-26-000029.json","markdown":"https://secwatch.observer/filing/0001690585-26-000029.md","text":"https://secwatch.observer/filing/0001690585-26-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/0001690585-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-20260612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:05:31.269348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}